

SPECIALTY GUIDELINE MANAGEMENT

SKYRIZI (risankizumab-rzaa)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Moderate to severe plaque psoriasis

Authorization of 6 months may be granted for treatment of moderate to severe plaque psoriasis for members who are 18 years of age or older when all of the following criteria are met:

1. Skyrizi is prescribed by, or in consultation with, a specialist in dermatology or rheumatology.
2. At least 10% of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected
3. Member meets either of the following criteria:
 - a. Member has had an inadequate response to at least a 3 month trial of methotrexate, cyclosporine or acitretin, or experienced clinically significant adverse effects from methotrexate, cyclosporine or acitretin
 - b. Member has had an inadequate response to at least a 3 month trial of phototherapy (e.g., UVB, PUVA), unless intolerance experienced
4. Skyrizi will not be used concomitantly with any other biologic DMARD (e.g. adalimumab, infliximab) or targeted synthetic DMARD (e.g. apremilast, tofacitinib).
5. Member has a pretreatment tuberculosis (TB) screening with a TB skin test or an interferon gamma release assay (e.g., QFT-GIT, T-SPOT.TB). *[Note: Members who have received Skyrizi or any other biologic DMARD or targeted synthetic DMARD (e.g., Xeljanz) are exempt from requirements related to TB screening in this Policy.]*

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members (including new members) who achieve or maintain positive clinical response after at least 4 months of therapy with Skyrizi as evidenced by low disease activity or improvement in signs and symptoms of the condition.

IV. QUANTITY LIMIT

Skyrizi has a quantity limit of 150mg (1 box) per 12 weeks, with post-limit for loading dose of 300mg per month.

V. REFERENCES

1. Skyrizi [package insert]. North Chicago, IL: AbbVie Inc.; April 2019.
2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol*. 2009;61:451-485.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011;65(1):137-174.
4. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. *Lancet*. 2018;392(10148):650-661.